Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.36 |
| ▸ | NT5E | P21589 | 4/20 | 0.35 |
| ▸ | CTSL | P07711 | 1/20 | 0.35 |
| ▸ | CTSB | P07858 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.34 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.34 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.34 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.34 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22569903 | 1.00 | PDE2A (0.41) | PDE2ABCHEHTR1AADORA1ADORA3 | |
| SCHEMBL29398438 | 0.93 | PDE2A (0.46) | PDE2ABCHEHTR1AADORA1ADORA3 | |
| SCHEMBL24557950 | 0.89 | HTR1A (0.37) | PDE2ABCHEHTR1ANT5ECA1 | |
| SCHEMBL22579642 | 0.88 | HTR1A (0.36) | PDE2ABCHEHTR1ANT5ECA1 | |
| SCHEMBL28406218 | 0.88 | BCHE (0.38) | PDE2ABCHEHTR1AADORA1ADORA3 | |
| SCHEMBL22569957 | 0.87 | HTR1A (0.38) | PDE2ABCHEHTR1ACA1CA2 | |
| SCHEMBL29398378 | 0.87 | HTR1A (0.38) | PDE2ABCHEHTR1ACA1CA2 | |
| SCHEMBL24557992 | 0.86 | PDE2A (0.38) | PDE2ABCHEHTR1ANT5ECA1 | |
| SCHEMBL22579773 | 0.86 | PTPN1 (0.39) | BCHEHTR1ANT5ESSTR1SSTR2 | |
| SCHEMBL24941082 | 0.85 | PDE2A (0.37) | PDE2ABCHEHTR1ANT5ECA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220204539-A1 | CD73 INHIBITORS | BIOARDIS LLC | 2022-06-30 | — | — | US | disclosed |
| US-20220204539-A1 | CD73 INHIBITORS | BIOARDIS LLC | 2022-06-30 | — | — | US | disclosed |
| EP-3956341-A1 | CD73 INHIBITORS | Bioardis LLC (US) | 2022-02-23 | — | — | EP | disclosed |
| WO-2020211672-A1 | CD73 INHIBITORS | BIOARDIS LLC (US) | 2020-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220204539-A1 | CD73 INHIBITORS | ENTPD5, ENTPD1, ENTPD2 | PDE2A 431/4885BCHE 663/4885HTR1A 2118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.